Volumina Medical, a clinical stage MedTech company developing novel biomaterials for dermatology and plastic surgery, announces the successful closing of their Series A round by existing and new investors. It will enable Volumina Medical to confidently advance its clinical program with its lead product AdipearlTM, and ultimately achieve market approval in key international markets.
AdipearlTM product is an innovative injectable dermal filler enabling the regeneration of soft tissues. This breakthrough innovation addresses a high unmet need of millions of patients that require the reconstruction or regeneration of tissues after surgery, disease or for aesthetic purposes. The product is currently being used in clinical trials by world-renowned KOLs in Europe.
The funding will be used to gather additional and valuable clinical data to bring AdipearlTM to the market and ultimately help millions of patients that currently lack natural and durable solutions for improving their health and wellbeing.